Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

Abstract

Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.